TUCSON, Ariz., July 22, 2016 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. announced today it will report second-quarter 2016 financial results on Monday, August 8th.
President and Chief Executive Officer, Lawrence Mehren, joined by Steve Reichling, Chief Financial Officer, will host a conference call to review the results at 4:15 p.m. ET.
The quarterly financial results will be accessible through the company's website at http://ir.axdx.com or through the Securities and Exchange Commission (SEC) on form 10-Q following the call.
To participate in the conference call, dial +1.888.317.6003 and enter the conference ID: 9700945.
International participants may dial +1.412.317.6061. Please dial in 10 minutes
prior to the start of the conference. A replay of the call will be available by telephone at +1.877.344.7529 (U.S.) or +1.412.317.0088 (international) using access code 10086925 until August 22, 2016.
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. ("Accelerate Diagnostics,") (Nasdaq:AXDX), is an in vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistance and hospital acquired infections. The company's fully automated ID/AST system, Accelerate Pheno™, and direct from positive blood culture test, Accelerate PhenoTest™ BC, utilize
proprietary molecular and phenotypic detection technologies which have the potential to substantially reduce the time to antimicrobial susceptibility results while achieving high sensitivity and specificity. For more information about Accelerate Diagnostics, visit www.acceleratediagnostics.com.
The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and "ACCELERATE PHENOTEST" logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.
Certain of the statements made in
this press release are forward looking, such as those, among others, about our projections as to when certain key business milestones may be achieved, including obtaining marketing authorization by the FDA of the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit for positive blood cultures, the commercial launch of the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit for positive blood cultures, the potential of our technology, the growth of the market, our estimates as to the size of our market opportunity and potential pricing, our competitive position and estimates of time reduction to results, and our future development plans and growth strategy. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Information about the risks and uncertainties faced by Accelerate Diagnostics is contained in the section captioned "Risk Factors" in the company's most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 9, 2016. In addition, the company's forward-looking statements could be affected by general industry and market conditions. Except as required by federal securities laws, the company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties or other contingencies.
Investors May Contact:
Laura Pierson, Accelerate Diagnostics, +1 520 365-3100
Reporters May Contact:
Andrew Chasteen, Accelerate Diagnostics, +1 520 365-3100
Source: Accelerate Diagnostics, Inc.
News Provided by Acquire Media